Ignite Creation Date:
2025-12-24 @ 10:41 PM
Ignite Modification Date:
2026-06-06 @ 6:13 PM
Study NCT ID:
NCT05699135
Status:
TERMINATED
Last Update Posted:
2024-04-24
First Post:
2022-12-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer
Sponsor:
Pfizer
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Bladder Cancer | View |
| None | Bladder Neoplasms | View |
| None | Bladder Tumors | View |
| None | Cancer of Bladder | View |
| None | Cancer of the Bladder | View |
| None | Malignant Tumor of Urinary Bladder | View |
| None | Neoplasms, Bladder | View |
| None | Urinary Bladder Cancer | View |
| None | Metastatic bladder cancer | View |
| None | Locally advanced bladder cancer | View |
| None | Urothelial carcinoma | View |
| None | Locally advanced urothelial carcinoma | View |
| None | Metastatic urothelial carcinoma | View |
| None | avelumab | View |
| None | avelumab maintenance | View |
| None | Canada bladder cancer | View |
| None | Non-interventional study | View |